Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Paclitaxel; Sorafenib
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 19 Oct 2020 Biomarkers information updated
- 09 Jun 2008 Actual initiation date is changed from Feb 2008 to Oct 2007 as reported by ClinicalTrials.gov.
- 09 Jun 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.